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RESEARCH
Heterogeneity in HIV and cellular 
transcription profiles in cell line models of latent 
and productive infection: implications for HIV 
latency
Sushama Telwatte1,2†, Sara Morón‑López1,2†, Dvir Aran3†, Peggy Kim1, Christine Hsieh1,2, Sunil Joshi1,2, 
Mauricio Montano2,4, Warner C. Greene2,4, Atul J. Butte3, Joseph K. Wong1,2 and Steven A. Yukl1,2* 
Abstract 
Background: HIV‑infected cell lines are widely used to study latent HIV infection, which is considered the main bar‑
rier to HIV cure. We hypothesized that these cell lines differ from each other and from cells from HIV‑infected individu‑
als in the mechanisms underlying latency.
Results: To quantify the degree to which HIV expression is inhibited by blocks at different stages of HIV transcription, 
we employed a recently‑described panel of RT‑ddPCR assays to measure levels of 7 HIV transcripts (“read‑through,” 
initiated, 5′ elongated, mid‑transcribed/unspliced [Pol], distal‑transcribed [Nef ], polyadenylated, and multiply‑sliced 
[Tat‑Rev]) in bulk populations of latently‑infected (U1, ACH‑2, J‑Lat) and productively‑infected (8E5, activated J‑Lat) 
cell lines. To assess single‑cell variation and investigate cellular genes associated with HIV transcriptional blocks, we 
developed a novel multiplex qPCR panel and quantified single cell levels of 7 HIV targets and 89 cellular transcripts in 
latently‑ and productively‑infected cell lines. The bulk cell HIV transcription profile differed dramatically between cell 
lines and cells from ART‑suppressed individuals. Compared to cells from ART‑suppressed individuals, latent cell lines 
showed lower levels of HIV transcriptional initiation and higher levels of polyadenylation and splicing. ACH‑2 and J‑Lat 
cells showed different forms of transcriptional interference, while U1 cells showed a block to elongation. Single‑cell 
studies revealed marked variation between/within cell lines in expression of HIV transcripts, T cell phenotypic mark‑
ers, antiviral factors, and genes implicated in latency. Expression of multiply‑spliced HIV Tat‑Rev was associated with 
expression of cellular genes involved in activation, tissue retention, T cell transcription, and apoptosis/survival.
Conclusions: HIV‑infected cell lines differ from each other and from cells from ART‑treated individuals in the mecha‑
nisms governing latent HIV infection. These differences in viral and cellular gene expression must be considered when 
gauging the suitability of a given cell line for future research on HIV. At the same time, some features were shared 
across cell lines, such as low expression of antiviral defense genes and a relationship between productive infection 
and genes involved in survival. These features may contribute to HIV latency or persistence in vivo, and deserve fur‑
ther study using novel single cell assays such as those described in this manuscript.
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Background
The persistence of HIV in long-lived latently-infected 
CD4+ T cells [1–5] continues to be a major barrier to a 
cure for HIV. Latently-infected CD4+ T cells are exceed-
ingly rare in HIV-infected ART-suppressed individuals 
(about 1 per million cells [6]), and no methods currently 
exist to isolate or characterize these cells without ex vivo 
activation, which reverses latency. Multiple different 
mechanisms have been implicated in HIV latency [7, 
8]. In peripheral blood mononuclear cells (PBMCs) and 
peripheral CD4+ T cells from HIV-infected ART-sup-
pressed individuals, we recently showed that the major 
reversible blocks to HIV expression are blocks to HIV 
transcriptional elongation, distal transcription/polyade-
nylation (completion), and splicing [9, 10], while in rectal 
CD4+ T cells we observed blocks to initiation, comple-
tion, and splicing [10]. However, the cellular gene prod-
ucts mediating these blocks to HIV expression remain 
unclear. It is extremely challenging to investigate these 
questions using cells from ART-suppressed individuals 
because no methods exist to distinguish latently-infected 
cells from uninfected cells or cells infected with defective 
or non-inducible proviruses.
The development of HIV-infected cell lines, such as 
U1, ACH-2, J-Lat, and 8E5 [11–15] cells, has led to 
many fundamental discoveries and greatly advanced 
our understanding of HIV infection and the establish-
ment of latency. These cell lines have been used in over 
600 publications pertaining to HIV (PubMed results: 
[“U1 cell” and HIV] = 378; [“ACH-2 cell” or “ACH2 cell” 
and HIV] = 181; [“J-Lat cell” or “J-lat cell” and HIV] = 51; 
[“8E5 cell” and HIV] = 44), and they continue to be used 
in studies to investigate mechanisms of latent HIV infec-
tion, design or evaluate assays to measure the HIV reser-
voir [16], and test new therapies to reverse latency [17] or 
silence latently-infected cells. They differ in the parental 
cell of origin (U1: U937 pro-monocytic cells; ACH-2 and 
8E5: A3.01 subclone of CEM T cells; J-Lat: Jurkat T cells), 
the replication capacity of the provirus (U1 and ACH-2 
are replication-competent but harbor mutations in Tat 
and TAR, respectively [18, 19], while 8E5 and J-Lat cells 
are replication-defective), whether they produce viral 
particles at baseline (8E5) or only after activation (U1, 
ACH-2, J-Lat), and their responses to different activating 
stimuli and latency-reversing agents.
In vitro mechanistic studies using cell lines have 
yielded important insights and enabled research in set-
tings where access to samples from HIV-infected individ-
uals is limited or where ex vivo samples are unsuitable for 
large-scale assays requiring many cells. While multiple 
primary cell models of latency [20–27] have been devel-
oped to more closely mimic latency in vivo, it is not clear 
whether the mechanisms of latency in these primary cell 
models are the same as those in ART-suppressed individ-
uals, and cell lines may have advantages in terms of their 
availability, ease of use, cost, frequency of infection, and 
known proviral sequence and integration site. Nonethe-
less, cell lines have inherent limitations that may reduce 
the degree to which they recapitulate latent HIV-1 infec-
tion and persistence in vivo. Some cell lines contain pro-
viral mutations, such as the TAR mutation in ACH-2 or 
Tat mutation in U1 [18, 19], that contribute to the main-
tenance of their latent state. Transformed cell lines con-
tinuously proliferate, which render them fundamentally 
different from quiescent resting CD4+ T cells that are in 
 G0 state [7]. Despite the clonal nature of their integration 
sites, the accumulation of cells with different proviral 
integration sites has been reported to occur in cell lines 
with replication-competent proviruses, such as ACH-2 
and U1, over successive rounds of passaging [28].
Understanding the regulation of HIV latency at 
bulk and single-cell levels in tractable models of HIV 
latency, such as cell lines, can potentially provide 
insights into the cellular factors that may regulate HIV 
latency in  vivo and may improve tools for screening 
new therapies designed to reactivate or silence latently-
infected cells [17]. However, it is unclear how closely 
HIV latency in cell lines compares to cells from HIV-
infected individuals. We hypothesized that the mecha-
nisms underlying HIV latency differ between cell lines 
and cells from HIV-infected ART-suppressed individu-
als. To quantify the degree to which HIV expression is 
reversibly inhibited by mechanistic blocks at various 
stages of HIV transcription, we compared the bulk HIV 
transcription profile for seven latently-infected cell 
lines (U1, ACH2, and J-Lat 6.3, 8.4, 9.2, 15.4 and 5A8 
clones; Table  1), three productively-infected cell lines 
(8E5, and reactivated J-Lat 9.2 and 5A8 clones), and 
cells from the blood of ART-suppressed individuals. We 
found that HIV-infected cell lines differed from each 
other and blood cells from ART-treated individuals 
in the blocks to HIV transcription underlying latency. 
To investigate the link between human and viral gene 
expression in individual cells, we also applied a novel 
panel of multiplex qPCR assays to quantify expression 
of seven HIV targets and 89 human genes in single cells 
from latently and productively HIV-infected cell lines. 
The expression of both HIV and cellular genes differed 
between cell lines, and we observed a surprising heter-
ogeneity within some clonal cell lines in the single cell 
levels of polyadenylated HIV RNA, multiply-spliced 
HIV RNA, and certain cellular transcripts. However, 
some common features were shared across cell lines, 
such as impairments in cellular antiviral defenses, and 
deserve further study for their contribution to HIV per-
sistence and latent infection in vivo.
Page 3 of 23Telwatte et al. Retrovirology           (2019) 16:32 
Results
HIV DNA levels differ between cell lines
As a surrogate measure of HIV infection frequency 
in each cell line, we quantified HIV DNA levels using 
ddPCR assays for 5 different proviral regions and nor-
malized them to cell numbers by DNA mass and by 
measured copies of the human gene Telomere Reverse 
Transcriptase (TERT) (Additional file  1: Fig. S1A, B). 
When normalized by DNA mass, U1 cells harbored an 
average of > 1 provirus per cell, as previously shown [12], 
and ACH-2, J-Lat 9.2 and J-Lat 5A8 harbored an average 
of 1 provirus per cell. In J-Lat 6.3 and J-Lat 8.4, we quan-
tified 0.7 proviruses/cell; in J-Lat 15.4, 0.6 proviruses/cell; 
and in 8E5 cells, 0.5 proviruses/cell (Additional file 1: Fig. 
S1A). When normalized by TERT, the HIV DNA levels 
were lower, and all cell lines except U1 and J-Lat 5A8 
showed an HIV infection frequency of < 1 provirus/cell 
(Additional file  1: Fig. S1B). These findings may reflect 
variability in HIV infection frequencies in cell lines and/
or inaccuracies in the methods used to measure or nor-
malize them in bulk cells, suggesting a role for single cell 
studies.
Table 1 Cell lines analyzed in this study from NIH AIDS reagents program and the Greene laboratory
nd not determined
Cell line Cell lineage Parental cell 
line
Major 
integration 
sites [28, 97]
Virus Replication 
competent 
virus
Viral mutation Proviral copies 
reported 
per cell
Virus expression 
phenotype
References
U1 Monocyte U937 AC079807.4 
non‑coding 
ORF (Chr.X)
HIV‑1 Yes Mutation in tat 2 Minimal constitutive 
virus expression
Inducible with 
cytokines + PMA
[12]
ACH2 Lymphocyte CEM NT5C3A LAV Yes Mutation in tar 1 Constitutively produces 
low levels of superna‑
tant RT and p24
Infectious HIV‑1 produc‑
tion inducible with 
PMA or TNFα
[13, 98]
J‑lat 6.3 Lymphocyte Jurkat nd HIV‑R7/E‑/GFP No Frameshift in 
env
Nef defective
1 Minimal constitutive 
virus expression 
(secretion of incom‑
plete viral particles)
Inducible with PHA or 
PMA ± ionomycin
[15]
J‑lat 8.4 Lymphocyte Jurkat FUBP1 HIV‑R7/E‑/GFP No Frameshift in 
env
Nef defective
1 Minimal constitutive 
virus expression 
(secretion of incom‑
plete viral particles)
Inducible with PHA or 
PMA ± ionomycin
[15]
J‑lat 9.2 Lymphocyte Jurkat PPP5C HIV‑R7/E‑/GFP No Frameshift in 
env
Nef defective
1 Minimal constitutive 
virus expression 
(secretion of incom‑
plete viral particles)
Inducible with PHA or 
PMA ± ionomycin
[15]
J‑lat 15.4 Lymphocyte Jurkat UBA2 HIV‑R7/E‑/GFP No Frameshift in 
env
Nef defective
1 Minimal constitutive 
virus expression 
(secretion of incom‑
plete viral particles)
Inducible with PHA or 
PMA ± Ionomycin
[15]
J‑lat 5A8 Lymphocyte Jurkat MAT2a HIV‑R7/E‑/GFP No Frameshift in 
env
Nef defective
1 Minimal constitutive 
virus expression 
(secretion of incom‑
plete viral particles)
Inducible with T cell 
activation (α‑CD3/
CD28 antibod‑
ies), > 3.3 μg/ml PHA 
or PMA ± ionomycin
[97]
8E5 Lymphocyte CEM nd LAV No Frameshift in 
pol
1 Constitutive expression 
of defective virus 
particles (no RT), with 
high p24 expression
[11, 99, 100]
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HIV transcription profile differs between cell lines and cells 
from ART‑suppressed individuals
To measure the degree to which different mechanisms 
inhibit HIV expression in each cell line, we meas-
ured the bulk cell levels of HIV transcripts that sug-
gest transcriptional interference from neighboring 
cellular genes (“read-through” transcripts that inhibit 
initiation from the HIV promoter) and transcripts that 
indicate HIV transcriptional initiation (TAR), 5′ elonga-
tion (“LongLTR”), mid transcription (Pol; also indicates 
unspliced), distal transcription (Nef), polyadenylation 
(“PolyA”), and multiple-splicing (“Tat-Rev”) (Fig.  1a, 
Additional file 1: Fig. S1C). To correct for differences in 
the infection frequencies between cell lines and PBMCs 
or peripheral CD4+ T cells from HIV-infected ART-
suppressed individuals, we calculated the average level 
of each transcript per provirus, as measured by the ratio 
of each HIV RNA region to levels of the R-U5-pre-Gag 
(LongLTR) HIV DNA region, which is present in one 
copy per provirus (Fig.  1b). Results were comparable 
when each HIV RNA was normalized to levels of the cor-
responding HIV DNA region measured using the same 
primers/probes (Additional file  1: Fig. S1D), suggesting 
that any differences between HIV RNA regions cannot 
readily be explained by proviral deletions or hypermuta-
tions in the primer/probe regions.
The unstimulated CD4 and PBMCs showed a con-
tinuous decrease from levels of initiated to 5′ elongated, 
mid-transcribed (Pol), distal transcribed (Nef), U3-pol-
yadenylated, and multiply-spliced HIV transcripts, con-
sistent with previously observed blocks to elongation, 
mid/distal transcription, polyadenylation, and splic-
ing (Fig. 1b; Additional file 1: Fig. S1C, D). The latently-
infected cell lines showed different patterns, with less of 
a decrease from initiated to polyadenylated transcripts, 
suggesting less block to elongation and completion.
HIV transcriptional initiation, as measured by TAR 
RNA/HIV DNA, tended to be lower in all latently-
infected cell lines than unstimulated CD4 or PBMCs, 
higher in activated CD4+ T cells and activated J-Lat 9.2 
cells, and even higher in the productively-infected 8E5 
cells and activated J-Lat 5A8 cells (Fig.  1b). In contrast, 
levels per provirus of polyadenylated HIV transcripts 
tended to be higher in all latent cell lines compared to 
unstimulated cells from ART-suppressed individuals.
Levels per provirus of U3-R-U5 “Read-through” tran-
scripts, which suggest transcriptional interference, were 
similar in ACH-2 cells and unstimulated CD4 or PBMCs, 
but the other latent cell lines tended to have lower levels. 
All unstimulated J-Lat clones and ACH-2 cells showed 
a surprising pattern where levels of initiated HIV tran-
scripts were comparable to polyadenylated transcripts, 
suggesting little transcriptional block to elongation or 
completion, but paradoxically, polyadenylated transcripts 
were much greater than 5′ elongated (LongLTR) or mid 
transcribed (Pol) transcripts. We found no evidence of 
false positives in the assays for polyadenylated HIV tran-
scripts or of inhibition in the assays for 5′ elongated or 
mid-transcribed (Pol) RNA or DNA. Moreover, levels of 
the “5′ elongated” and Pol HIV DNA were almost exactly 
the same and showed the expected 1:2 ratio to levels of 
the TAR and U3–U5 (read-through) HIV DNA regions 
(which are present at both ends of the provirus), suggest-
ing that the differences in the HIV RNA are not explained 
by proviral mutations (Additional file 1: Fig. S1A, B). The 
surprising pattern of HIV RNAs in these J-Lat clones and 
ACH-2 cells suggests that many of their HIV transcripts 
result from upstream cellular run-on transcripts that 
continue into the proviral 5′ U3 region (upstream of the 
normal HIV transcription start site in the TAR sequence 
of the R region) but are polyadenylated after the R region 
of the 5′ LTR, prior to the U5 or Gag regions, so they are 
not detected by the U3–U5 “Read-through” assay. This 
data accords with prior findings in the J-Lat 9.2 clone, 
which described human/HIV hybrid transcripts that 
mostly terminated in the 5′ LTR [29]. Our data suggest 
all 5 J-Lat clones also have a form of transcriptional inter-
ference where most HIV transcripts are cellular run-on 
transcripts, but that they terminate prematurely because 
the transcription machinery recognizes the polyadenyla-
tion signal in the 5′ LTR.
Compared to unstimulated CD4 and PBMCs, U1 cells 
showed less of a decrease from 5′ elongated to distally 
transcribed and polyadenylated transcripts, suggesting 
(See figure on next page.)
Fig. 1 HIV genome and the targets for transcription profiling assays and bulk cell‑associated HIV RNA levels. a This schematic shows the genetic 
organization of proviral HIV DNA and the HIV ‘transcription profiling’ assays targeting specific HIV RNA sequence regions suggesting transcriptional 
interference (Read‑through) and progression through blocks to HIV transcriptional initiation (TAR), 5′ elongation (LongLTR), mid transcription 
(Pol), distal transcription (Nef ), polyadenylation (PolyA), and multiple splicing (Tat‑Rev). b HIV RNA levels normalized to HIV DNA (provirus) 
copies (ratio of each HIV RNA to LongLTR HIV DNA) (mean of 2 replicate measures of HIV RNA and DNA). c Ratio of one HIV RNA to another: 
Read‑through normalized to TAR (transcriptional interference), LongLTR to TAR (elongation), Pol to LongLTR (mid transcription), Nef to LongLTR 
(distal transcription), PolyA to LongLTR (completion) and Tat‑Rev to LongLTR (multiple splicing). For PBMCs, CD4+ T cells, and activated CD4+ T cells 
from HIV‑infected ART‑suppressed individuals (b, c), each individual is shown as a dot, the column height indicates the median, and bars represent 
25–75%
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less block to distal transcription and completion, while 
little or no decrease was observed in the ACH-2 cells 
and productively-infected cells. These data suggest that 
latently-infected cell lines differ from each other and 
from cells from ART-suppressed individuals in the HIV 
transcriptional blocks underlying latency (Additional 
file 2: Fig. S2).
HIV latency in cell lines may be driven by transcriptional 
interference and/or blocks to elongation
To quantify the progression through various stages of (or 
blocks to) HIV transcription, we calculated the ratios of 
different HIV RNA regions (Fig. 1c and Additional file 3: 
Table  S1). The ratio of U3-R-U5 Read-through to initi-
ated (TAR) HIV transcripts was higher in ACH-2 cells 
(0.10) than the other cell lines or unstimulated CD4 or 
PBMCs, suggesting more transcriptional interference. 
In the J-Lat clones, the ratio of U3-R-U5 Read-through 
to initiated HIV transcripts was generally comparable to 
unstimulated CD4 or PBMCs. However, the large excess 
of initiated and polyadenylated over 5′ elongated or mid 
elongated transcripts in the J-Lat and ACH-2 cells sug-
gests a different form of transcriptional interference in 
which cellular run-on transcripts get polyadenylated 
after the R region of the 5′ LTR.
The low ratios of 5′ elongated to initiated transcripts 
(LongLTR/TAR) in U1 cells (0.11) and most J-Lat 
clones were comparable to those in unstimulated CD4 
or PBMCs, suggesting similarly low levels of elonga-
tion. In contrast, the ACH-2 cells showed a much higher 
ratio of 5′ elongated to initiated HIV transcripts (0.43), 
which was comparable to activated CD4 T cells and the 
productively-infected cell lines, suggesting little block to 
elongation. In all cell lines, levels of mid and distal HIV 
transcription (as measured by the ratio of Pol or Nef to 
LongLTR) were similar to or higher than the unstimu-
lated CD4 or PBMCs. Likewise, the ratio of polyade-
nylated to 5′ elongated HIV transcripts was higher in all 
cell lines than in unstimulated CD4 or PBMCs, suggest-
ing higher levels of transcriptional polyadenylation or 
“completion” in the latent cell lines (although in the case 
of the J-Lat clones and ACH-2, many of these are not full 
length).
While we have previously used the ratio of multiply-
spliced to polyadenylated HIV RNA (Tat-Rev/PolyA) 
as a measure of splicing, the high levels of prematurely-
terminated, polyadenylated transcripts in the J-Lat and 
ACH-2 cells confound interpretation of this ratio. The 
ratios of multiply-spliced to initiated and 5′ elongated 
transcripts were higher in all latent cell lines than in the 
unstimulated CD4/PBMCs (and sometimes compara-
ble to activated CD4+ T cells), suggesting less baseline 
block to splicing. At the same time, J-Lat 9.2 and 5A8 
cells showed an increase in these ratios with activation, 
suggesting some reversible block. These data suggest that 
the mechanisms that regulate HIV latency differ between 
latently-infected cell lines and cells from ART-suppressed 
individuals, with inhibition of HIV transcriptional initia-
tion due to different forms of transcriptional interference 
in the ACH-2 and J-Lat cells, blocks to HIV-specific tran-
scriptional initiation and elongation in U1 cells, and less 
baseline block to completion or splicing in all latent cell 
lines (Additional file 2: Fig. S2).
Single cell multiplexed qPCR is sensitive and reproducible 
for detection of cellular and HIV transcripts
To determine whether there is cell-to-cell variability 
within cell lines, and to investigate cellular genes that 
may be associated with blocks to HIV expression, we 
developed a novel panel of assays to quantify multiple 
HIV targets and cellular transcripts at the single cell level 
using the Fluidigm C1 and Biomark HD platforms. Our 
96-assay multiplex qPCR panel included five assays for 
different regions of HIV DNA or RNA (TAR, LongLTR, 
Gag, Pol, Nef ), two assays specific for HIV RNA (for 
U3-polyadenylated [PolyA] and multiply-spliced [Tat-
Rev] HIV transcripts), and 89 human cellular RNAs. 
Aside from a few housekeeping transcripts, the cel-
lular genes (Additional file  4: Table  S2) were all chosen 
based on prior studies suggesting their importance for 
HIV infection and/or latency. To simplify the analysis, 
we divided these cellular genes into 4 broad categories: 
(1) housekeeping transcripts; (2) markers of T cell phe-
notype and function (including markers of T cells and 
subsets, HIV coreceptors, markers of T cell activation 
and proliferation, negative T cell regulators such as PD-1, 
genes involved in apoptosis or survival, etc.); (3) cellular 
antiviral defenses, including restriction factors; and (4) 
genes implicated in human transcription/polyadenyla-
tion/splicing, HIV transcription, and HIV latency.
Validations were performed to determine the detection 
limit of each HIV assay, batch variation, correlation with 
bulk cell expression, and Biomark HD reproducibility. 
A multiply-spliced, polyadenylated HIV RNA standard 
and an HIV virion standard [9] were used to determine 
the sensitivity of our assays for HIV RNA in the single 
cell approach. As few as 5 copies of HIV RNA could be 
detected for all assays except PolyA, which was less effi-
cient in this assay system than the bulk cell RT-ddPCR 
(Additional file 5: Fig. S3).
For the single cell analysis of viral and cellular gene 
expression, we studied 3 different latently-infected cell 
lines (U1, ACH-2, J-Lat 9.2) plus two different produc-
tively-infected cell lines (8E5, activated J-Lat 9.2). Because 
the bulk cell HIV transcription profile suggested very simi-
lar mechanisms of latency in all five J-Lat clones, we chose 
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to study only one J-Lat clone at the single cell level; J-Lat 
9.2 was chosen because it has been well-characterized with 
regard to the mechanism of latency (transcriptional inter-
ference). We did not include cells from ART-treated indi-
viduals because the expected frequency of HIV-infected 
cells (about 1 in 1000 circulating CD4+ T cells) is far too 
low expect capture of any HIV-infected cells with the C1 
chips, which capture a maximum of 96 cells.
Cell viability was greater than 90% for all cell lines tested 
(median: 95%), except activated J-Lat 9.2 (median 86% 
viability prior to C1 integrated fluidic circuit loading). 
Each cell line was tested in at least two batches (Fig. 2a, 
Additional file  6: Fig. S4), and we selected cDNA from 
individual cells (11  J-Lat 9.2 and 3 U1 cells) for repeat-
testing in two independent Biomark experiments (Addi-
tional file  6: Fig. S4). A total of 40 unique U1 cells, 40 
ACH-2, 44 8E5, 41 unstimulated J-Lat 9.2, and 45 acti-
vated J-Lat 9.2 were analyzed (Additional file 7: Table S3). 
At least one HIV target was detected in 40/40 U1, 40/40 
ACH-2, 43/44 8E5, 40/41 unstimulated J-Lat 9.2, and 
Fig. 2 Single‑cell multiplex qPCR analysis of HIV cell line models. a Principal component analysis of the gene expression levels (right plot: 
dimension 2 vs. dimension 1; left: dimension 3 vs. dimension 1). Single cells for each cell line are indicated by color and different shapes denote 
independent assays (batch). No batch effects were observed (P < 0.001, Wilcoxon rank sum test). b Scatter plots of average expression levels 
(40‑cycle threshold; ~ log2) of all targets in single cells (y axis) vs. bulk cells (x axis) for each cell line and overall (box). High concordance was 
observed (R > 0.86 for all cell lines)
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45/45 activated J-Lat 9.2 cells. For each cell line, the aver-
age single cell expression of all targets correlated with 
bulk cell expression (R ≥ 0.86; Fig. 2b). With repeat testing 
of the cDNA from individual cells, levels of HIV and cel-
lular targets were highly reproducible from one Biomark 
run to the next (Additional file 6: Fig. S4A), and the “drop 
out” frequency was relatively low, even for low expression 
targets (Additional file  6: Fig. S4B). Batch variation was 
formally assessed using the ComBat method [30], but this 
did not appreciably alter the analysis (tSNE plot; Addi-
tional file 8: Fig. S5), so further analyses were conducted 
without batch correction adjustment. These validations 
indicate that the gene expression analyses using the Bio-
mark system were highly sensitive and reproducible.
Host gene expression accounts for most of the difference 
between cell lines
We hypothesized that differences between cell lines would 
reflect the degree of HIV expression (latent vs. produc-
tive), especially because many of the cellular genes in our 
panel were selected for their reported associations with 
HIV transcription and latency. Contrary to our expecta-
tions, the tSNE and PCA plots revealed clustering driven 
primarily by host gene expression. U1 cells, which are 
derived from a monocytic cell line [12], formed a distinct 
cluster in the tSNE plot (Additional file 8: Fig. S5). ACH-2 
and 8E5 cells, which are both derived from a human T cell 
line originating from acute lymphoblastic leukemia [11, 
13, 14, 31, 32], clustered together in both the PCA and 
tSNE plots despite the fact that one is latently-infected 
and the other is productively-infected (Fig. 2a, Additional 
file 8: Fig. S5). Furthermore, both untreated and activated 
J-Lat 9.2 cells clustered in close proximity to one another 
despite disparities in expression of both HIV and cellular 
targets (Fig. 2a, Additional file 8: Fig. S5).
In the principal component analysis, a total of 46.9% of 
the variation was driven by dimension 1 (which distin-
guished U1, ACH-2/8E5, and J-Lat cells) and dimension 2 
(which distinguished ACH-2/8E5 from the others), which 
were both driven by clusters of host genes (Fig. 2a, Addi-
tional file  9: Fig. S6). HIV Nef was included in a cluster 
with CD4, CD44, and interferon α (IFNA1; IFNα), but 
the role of Nef was confounded by the fact that this HIV 
region is deleted in J-Lat cells but not the other cell lines 
(Fig. 2a, Additional file 9: Fig. S6). Dimension 3 (which dis-
tinguished unstimulated J-Lat from the others) was driven 
by all the other HIV targets (including TAR, LongLTR, 
Gag, Pol, PolyA, and Tat-Rev), but accounted for only 
5.9% of the variation observed. Taken together, these data 
suggest that most of the observed difference between 
latently- and productively-infected cell lines is driven by 
host gene expression rather than HIV expression.
Single cell analysis reveals cell‑to‑cell variation in HIV 
target levels
To determine whether there is single cell variation 
in HIV infection or transcription within cell lines, we 
measured levels of HIV TAR, LongLTR, Gag, Pol, Nef, 
PolyA and Tat-Rev at the single cell level and visual-
ized the range in levels across all cells using violin plots 
(Fig.  3a) and heat maps (Fig.  3b). The average HIV 
expression in single cells tended to mirror our observa-
tions in bulk cell analyses (Fig. 1b), with several impor-
tant distinctions. Despite the sensitivity of our Tat-Rev 
assay (Additional file 5: Fig. S3), we detected Tat-Rev in 
none of the 41 untreated J-Lat 9.2 cells and only 3/40 
U1 cells, consistent with our bulk studies that esti-
mate a frequency of < 0.1 copies per provirus (Fig. 1b). 
Tat-Rev was detected in 15/40 ACH-2 cells, 30/44 8E5 
cells, and 23/45 activated J-Lat 9.2 cells (Fig. 3b); all 3 
cell lines showed a bimodal expression that is masked 
in bulk cell analyses. The PolyA assay performed less 
efficiently than the other HIV assays in the Biomark 
system (Additional file 5: Fig. S3), so the lower levels of 
these transcripts at the single cell level do not reflect 
our observations in bulk cells using RT-ddPCR.
As expected, the levels of specific HIV targets varied 
considerably between cell lines designated ‘latently’ and 
‘productively’ infected (Fig. 3a, b). Of the three latently-
infected cell lines (ACH-2, J-Lat 9.2 and U1), J-Lat 9.2 
tended to exhibit the lowest levels of all HIV targets 
except PolyA, which was detected more frequently in 
J-Lat 9.2 than in U1 cells (note that Nef is not present 
in the full-length integrated HIV construct of J-Lat cells 
[15]). This finding was consistent with our observations 
in bulk cells (Fig. 1b). U1 and ACH-2 cells showed com-
parable levels of HIV TAR, while ACH-2 cells showed 
higher median levels of the other HIV targets and a 
higher frequency of Tat-Rev+ cells. U1 cells also tended 
to exhibit less variation in single cell HIV levels (Fig. 3a, 
b). U1 and J-Lat 9.2 cells exhibited the lowest levels of 
HIV expression, which accords with their ‘latent’ phe-
notype and may more closely model levels observed in 
ex vivo CD4+ T cells from HIV-infected individuals.
On activation of J-Lat 9.2, we observed marked upreg-
ulation of all HIV targets, including polyadenylated 
(PolyA) and multiply-spliced (Tat-Rev) HIV transcripts 
(Fig. 3a, b). Activated J-Lat 9.2 and productively-infected 
8E5 cells demonstrated higher median levels of all HIV 
targets when compared to the three latently-infected cell 
lines. Both activated J-Lat 9.2 and 8E5 cells also showed 
cell-to-cell variability in all HIV targets, with bimodal 
expression of polyadenylated and multiply-spliced HIV 
transcripts. These results help confirm the differences 
between cell lines that were observed through the bulk 
cell measurement of HIV transcript levels but also reveal 
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a surprising heterogeneity in single cell levels of polyade-
nylated and multiply-spliced HIV transcripts within the 
clonal populations of ACH-2, 8E5, and activated J-Lat 
cells.
Single cell HIV levels suggest blocks to HIV transcription 
in latent cell lines
Within individual cells, we observed differences in lev-
els of HIV regions, consistent with previously observed 
blocks to HIV transcription (Fig.  1). In cell lines desig-
nated as ‘latent’ (ACH-2, J-Lat 9.2, and U1), correlations 
tended to be stronger between adjacent HIV regions and 
weaken with distance along the proviral genome (Fig. 3c; 
the correlations between Nef and other transcripts are 
confounded by the lack of Nef in the integrated provirus 
in J-Lat 9.2 cells and were not included in these analy-
ses). In the latent cell lines, 5′ regions (TAR, LongLTR, 
Gag, and Pol) correlated strongly with each other but 
weakly with PolyA and Tat-Rev, which could reflect 
transcriptional blocks and/or the fact that the latter 
two assays are RNA-specific. In contrast, the produc-
tive cell lines showed greater correlations between PolyA 
or Tat-Rev and the 5′ targets (TAR, LongLTR, Gag) 
(Fig. 3c). Moreover, the correlations between most HIV 
Fig. 3 Single cell differences in HIV target levels. a Violin plots representing spread and variability of HIV target levels (40‑cycle threshold). Individual 
cells are denoted by dots and median levels are indicated by horizontal lines. b Heatmap of cell‑to‑cell variation in levels of each HIV target (rows). 
Cells are grouped on the basis of cell line and ordered from high to low level of HIV TAR. Each vertical line represents a single cell. Color scale 
(below) indicates HIV target levels. c Correlation matrices for levels of each HIV target in latently‑infected (U1, ACH‑2, J‑Lat 9.2; upper panel) and 
productively‑infected (activated J‑Lat 9.2 and 8E5; lower panel) cell lines. Nef has been excluded from these analyses. Color scale denotes Spearman 
coefficients
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transcripts were significantly greater in the productive 
cell lines (Spearman coefficient > 0.8 for all correlations 
except Pol), suggesting that existing blocks to tran-
scription were reversed on stimulation (J-Lat) or that 
minimal blocks to transcription operate in productively-
infected cells (8E5).
HIV‑infected cell lines vary in T cell phenotypic markers 
and some genes implicated in latency
We hypothesized that specific cellular factors are likely to 
be associated with differential HIV transcription in HIV-
infected cell lines. Accordingly, we performed hierarchi-
cal clustering (by HIV TAR level) of our gene expression 
data for T cell phenotypic markers (Fig.  4a), factors 
reportedly associated with HIV transcription or latency 
(Fig.  4b), and cellular antiviral or restriction factors 
(Fig. 4c). The expression of housekeeping genes (GAPDH, 
RPL13a and PPIA) was high across all cell lines (Addi-
tional file 10: Fig. S7). Strikingly, J-Lat 9.2 cells expressed 
little or no CD4 even though they expressed high levels 
of T cell receptor alpha chain (TCRA), CD3 delta (CD3), 
and CD28 (Fig.  4a). In contrast, ACH-2 and 8E5 cells 
expressed CD3 and low, bimodal expression of CD4 but 
little or no TCRA or CD28. Overall, T cell phenotypic 
and functional markers were expressed at similar aver-
age levels in ACH-2 and 8E5 despite their divergent levels 
of HIV targets. As expected, monocyte-derived U1 cells 
expressed CD4 but not the T cell phenotype/function-
associated targets in our panel, including TCRA, CD3 
delta, CD28, CTLA-4, transcription factor 7 (TCF7), and 
nonreceptor protein-tyrosine kinase p56 (LCK) (Fig. 4a). 
Of the 5 cell types, only the activated J-Lat cells expressed 
programmed cell death protein 1 (PD-1) and CTLA-4 
transcripts (Fig. 4a).
We also observed considerable cell-to-cell variation in 
expression of some genes reportedly associated with HIV 
transcription or latency, including histone methyl trans-
ferase SUV39H1 in U1 cells, and TNF Receptor Super-
family member 8 (TNFRSF8, CD30) in J-Lat 9.2, ACH-2, 
and 8E5 cells (Fig.  4b). Nonetheless, J-Lat 9.2, ACH-2, 
and 8E5 expressed many of the genes in our panel that 
are reportedly associated with HIV transcription and/or 
latency (Fig.  4b, Additional file  10: Fig. S7). In contrast, 
U1 exhibited limited expression of many of these genes 
(zinc-finger transcription factor BCL11B, TNF Recep-
tor Superfamily Member 4 [TNFRSF4, OX40, CD134], 
PR domain zinc finger protein 1 [PRDM1, Blimp-1], 
ATF-3, and TNFRSF8 [CD30]) and exhibited generalized 
low RNA expression. Compared to the latent cell lines 
and even 8E5, activated J-Lat 9.2 exhibited higher aver-
age expression levels of most genes implicated in HIV 
transcription or latency (Fig.  4a, b). These data under-
score similarities and differences between cell lines in 
expression of some genes that have been implicated in 
HIV latency, as well as heterogeneity within clonal cell 
lines in expression of some of these genes.
HIV‑infected cells lines may have impairments in antiviral 
defenses
To investigate whether downregulation of cellular antiviral 
defenses could contribute to persistent HIV-infection or 
latency in cell lines, we measured single cell expression of 
cellular antiviral genes, including restriction factors. The 
expression of constitutive apolipoprotein B mRNA-editing 
catalytic polypeptide-like (APOBEC) variants APOBEC3G 
and APOBEC3F differed among the cell lines, with lit-
tle or no expression of APOBEC3G (U1) and APOBEC3F 
(U1, ACH-2, and 8E5) to high expression levels in acti-
vated J-Lat 9.2 (Fig.  4c). IFNα was not detected in J-Lat 
9.2 cells irrespective of activation state, while U1, ACH-2, 
and 8E5 expressed IFNα but often did not express Inter-
feron Response Factor 9 (IRF 9) (Fig. 4c). However, IRF9, 
Bone marrow Stromal antigen 2 (BST2, CD317, tetherin), 
and Signal Transducer and Activator of Transcription 1 
(STAT1) were strongly upregulated with activation of J-Lat 
9.2 cells (Fig.  4c). All cell lines tested demonstrated little 
or no expression of SAMHD1 (Fig.  4c), which is highly 
expressed in resting CD4+ T cells and reportedly sup-
presses HIV-1 LTR-driven gene expression [33].
We also measured single cell expression of antiviral 
pattern recognition receptors (PRR), including cytoplas-
mic viral RNA sensors (Retinoic acid-Inducible Gene 1 
[RIG-I], Melanoma Differentiation-Associated protein 5 
[MDA5]) and viral DNA sensors (Cyclic GMP-AMP Syn-
thase [C-GAS], Interferon gamma Inducible Protein 16 
[IFI16]) (Fig. 4c). Expression of RIG-I was variable among 
the cell lines tested, ranging from low expression in U1 to 
strong upregulation in activated J-Lat 9.2 (Fig. 4c). Simi-
larly, MDA5 levels were low in U1, ACH-2 and 8E5 but 
comparatively higher in J-Lat 9.2, particularly with acti-
vation (Fig. 4c).
On the other hand, J-Lat 9.2 cells expressed very little 
C-GAS, even upon activation (Fig.  4c), although most 
J-Lat 9.2 cells expressed IFI16 (Fig. 4a; Additional file 10: 
Fig. S7), the levels of which were increased on activation. 
U1 cells also expressed very little C-GAS, in contrast to 
both ACH-2 and 8E5, in which C-GAS expression was 
comparatively higher (Fig.  4c). The most genetically-
similar cell lines, ACH-2 and 8E5, tended to express the 
same antiviral factors, with no evidence to suggest that 
increased HIV expression (as observed in 8E5) results in 
modulation of these factors at the transcriptional level. 
Interestingly, low/no expression of different antiviral 
factors was observed in each cell line, suggesting that 
inherently attenuated antiviral responses contribute to 
persistent HIV infection and/or latency in these cell lines.
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HIV RNA expression correlates with host gene expression 
in J‑Lat cells
The cellular genes in our panel were selected for their 
prior reported associations with HIV infection and 
latency. We hypothesized that expression of specific cel-
lular factors associated with HIV transcription/latency 
or antiviral responses might correlate with the levels of 
HIV targets across different cell lines. To address this 
Fig. 4 Single cell variation in cellular gene expression. Single cell RNA levels are shown for cellular genes associated with a T cell phenotype and 
function; b HIV transcription and latency; and c antiviral and restriction factors. Cells are grouped by cell line and ordered from high to low level of 
HIV TAR. Each vertical line represents a single cell. Rows indicate different genes. Color scale (below) denotes expression level (40‑CT). Dendrograms 
of unsupervised clustering are indicated to the left of heat map. Heatmaps illustrate cell‑to‑cell variation in cellular gene expression. Violin plots are 
shown for selected host genes in each category, with individual cells denoted by dots
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question, we measured the correlation between expres-
sion of each cellular gene and each HIV target in each cell 
line (Fig. 5a). In U1, ACH-2 and 8E5, no significant corre-
lations were observed (after correction for multiple com-
parisons) except for those driven by the low detection of 
targets (Additional file 11: Fig. S8).
In unstimulated J-Lat 9.2, however, we observed many 
cellular genes for which expression positively corre-
lated with HIV targets, and this correlation was also 
observed with housekeeping genes, suggesting that HIV 
transcription in unstimulated J-Lat 9.2 cells reflects 
the degree of human cellular transcription (Fig.  5a). 
Positive correlations with higher correlation coefficient 
values and FDR < 0.05 included: CCR5, BCL11B, cyc-
lin-dependent kinase 9 (CDK9), CREB Binding Protein 
(CREBBP), and STAT1 (positively correlated with TAR, 
LongLTR, and Gag; Fig.  5a and Additional file  12: Fig. 
S9). In activated J-Lat 9.2 cells, the correlation coef-
ficient values were lower for all but a small subset of 
human genes (including STAT1, FOSB, EGR1, CD3, 
TCF7, CCR5, and CD69), and FDR < 0.05 was observed 
only with CD69, which correlated positively with multi-
ple HIV targets, including Tat-Rev (Fig.  5a; Additional 
file 12: Fig. S9). CD69 increases transiently after T cell 
activation but has also been described as a marker for 
tissue resident memory T cells. Surprisingly, no sig-
nificant correlations were observed between the HIV 
targets and other putative markers of T cell activation 
(including CD25, HLA-DR, CD38) in the activated 
J-Lat 9.2 cells, suggesting that the heterogeneity in HIV 
expression in these cells may not simply reflect differ-
ences in the degree of activation. Moreover, the cellular 
factors that correlated with HIV expression in unstimu-
lated or activated J-Lat 9.2 cells (such as CD69) showed 
no correlation or even trends towards opposite correla-
tions with HIV targets in the other cell lines. The lack 
of a consistent correlations across all cell lines could 
reflect differences in the genetic backgrounds of the 
various cell lines or differences in the mechanisms that 
maintain latency in each cell line.
To further delineate differential expression mediated 
by activation, we compared expression of all targets 
between untreated and activated J-Lat 9.2 (Additional 
file  13: Fig. S10). In addition to increased expression of 
HIV targets on activation, we found upregulation of 
multiple phenotype/function associated genes, includ-
ing T-box transcription factor (t-bet), B Cell Lymphoma 
6 (BCL6), CD44, TCRA and CD69, of which the most 
marked fold change was observed in t-bet expression 
(Additional file  13: Fig. S10). Multiple antiviral factors, 
including APOBEC3G, Cyclin-dependent Kinase Inhibi-
tor 1A (CDKN1A), RIG-I, MDA5, Interferon Regulatory 
Factor (IRF9), and STAT1, also increased in expression 
on activation (Additional file  13: Fig. S10). Notably, 
increased HIV expression also coincided with increased 
expression of OX40, a cell survival associated receptor, 
and NFΚBIA, which plays a role in mediating the tran-
scriptional activity of NFΚB (Additional file 13: Fig. S10). 
Two of the most differentially expressed genes, OX40 and 
CDKN1A, both play anti-apoptotic roles. Although acti-
vation of the J-Lat 9.2 cells increased expression of both 
HIV and cell survival associated factors, it is not clear 
whether these are independent effects of activation or 
whether there is a link between HIV expression and cel-
lular factors involved in apoptosis/survival.
Tat‑Rev+ cells show differential expression of genes 
associated with activation, transcription, and cell survival
Multiply-spliced Tat-Rev RNA has been proposed as a 
marker for productive infection, but we found single cell 
variation in Tat-Rev RNA even in the activated or pro-
ductively-infected cells. To further investigate cellular 
factors that may be associated with HIV splicing and/
or productive infection, we next determined how Tat-
Rev+ and Tat-Rev− cells within each cell line differ in 
the other HIV targets and expression of human genes. 
In activated J-Lat 9.2 and 8E5, the Tat-Rev+ cells exhib-
ited higher levels of HIV TAR, LongLTR, Gag, Pol, and 
Poly A (FDR < 0.05; Fig.  5b), reaffirming our previous 
correlations that suggest higher expression of other HIV 
targets occurs in cells that also express Tat-Rev (Fig. 3c). 
Tat-Rev+ and Tat-Rev− cells differed in their expres-
sion of cellular factors involved in activation (CD25, 
CD28, CD69), tissue retention (CD69), transcription 
(BCL6, FosB, ATF3, RORC, and P300/CBP-Associated 
Factor [PCAF]), and apoptosis/survival [TNFRSF4/
OX40, Fas], but the specific genes varied between cell 
lines and sometimes showed opposite expression in dif-
ferent cell lines (Fig.  5b). Within the activated J-Lat 
9.2 cells, Tat-Rev+ cells showed less expression of the 
early activation marker CD25 (despite a trend towards 
more CD69), while within the 8E5 cells, Tat-Rev+ cells 
showed lower expression of CD69 and the T cell corecep-
tor CD28. These findings suggest that the differences in 
HIV expression are not entirely driven by differences in 
T cell activation. Tat-Rev+ 8E5 cells showed lower lev-
els of the transcription regulators FosB and PCAF, while 
Tat-Rev+ ACH-2 cells showed higher levels of BCL6 and 
PCAF. Tat-Rev+ ACH-2 cells showed lower expression 
of the pro-apoptotic factor Fas, while Tat-Rev+ 8E5 cells 
had lower levels of the survival factor OX40/TNFSR4. 
Taken together, these data suggest a complex relationship 
between productive HIV infection and genes involved in 
activation, transcription, and apoptosis/survival.
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Fig. 5 Correlation between HIV targets and cellular transcripts. a Correlation matrix showing degree of correlation between expression of each 
cellular gene (columns) and each HIV target (rows). HIV targets are grouped by cell line. Color scale (right) indicates Spearman r values. b Differential 
expression of cellular genes between Tat‑Rev+ and Tat‑Rev− subpopulations of ACH‑2, activated J‑Lat, and 8E5 cells. Color scale denotes difference 
in expression level  (log2) in Tat‑Rev+ cells. P values were calculated using the Wilcoxon rank sum test and corrected for false discovery rate (FDR) 
using the Benjamini–Hochberg correction; asterisks (*) denote FDR‑adjusted P values < 0.05. Dendrograms (above) show unsupervised clustering of 
cellular factors. Cellular genes for which no expression was detected were excluded from these analyses
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Discussion
This study provides an in-depth analysis of HIV tran-
script profiles and cellular gene expression in commonly-
studied HIV-infected cell lines. We found that all cell 
lines differ from each other and from blood cells from 
HIV-infected ART-suppressed individuals in the HIV 
transcriptional blocks underlying latency. We observed 
marked variation in HIV and cellular gene expression 
both between and within cell lines, which has not been 
previously characterized, but we also identified several 
features that were common across multiple cell lines, 
such as low expression of cellular antiviral factors.
U1 cells showed a strong block to HIV transcriptional 
elongation, which is consistent with previous studies 
showing that these cells harbor a mutation in Tat and 
suboptimal levels of Tat protein [34]. U1 cells may also 
have a block to HIV transcriptional initiation, since HIV 
transcriptional initiation was lower than in cells from 
ART-suppressed individuals and prior studies have also 
showed alterations in the nuclear factor-kappa B (NF-κB) 
moieties [35]. However, we did not measure the extent 
to which these blocks can be reversed by monocyte-acti-
vating stimuli. It is also worth noting that U1 cells har-
bor an average of 2 proviruses per cell, so it is possible 
that different mechanisms inhibit expression of the two 
proviruses.
Prior publications have suggested that ACH-2 cells also 
have a block to elongation, which has been attributed to 
a mutation in the TAR region  (C37 → T) [18]. In contrast, 
we observed a high ratio of elongated to initiated (TAR) 
transcripts in the ACH-2 cells, suggesting little block 
to elongation, though it was possible that our meas-
ures of TAR RNA were not accurate despite correcting 
our probe sequence for the mutation. The ratio of read-
through (U3-R-U5) to initiated transcripts was higher 
in the ACH-2 cells than other cell lines or most ART-
suppressed individuals, suggesting that transcriptional 
interference operates to a greater degree in this cell line. 
Transcriptional interference has been described in J-Lat 
clones [29], but to our knowledge, this is the first time it 
has been shown in ACH-2 cells.
In all the J-Lat clones studied, we observed a surpris-
ing pattern where levels of initiated (TAR) and polyade-
nylated (U3-polyA) HIV transcripts were much greater 
than 5′ elongated (LongLTR) or mid-transcribed (Pol) 
transcripts. The best explanation for this pattern is that 
most of these transcripts are hybrid human/HIV run-on 
transcripts that contain the 5′ U3 region and the TAR 
loop but become prematurely terminated and polyade-
nylated in the 5′ LTR. Other explanations are possible, but 
seem less likely. The measured levels of polyadenylated 
transcripts could be falsely high, but prior validations 
have shown similar efficiencies for all the HIV RNA assays 
[9], with rare false positives that are generally limited to 
one droplet, while the J-Lats showed many PolyA+ drop-
lets at the expected amplitude and the negative controls 
remained negative. Moreover, it seems too much of a 
coincidence that levels of polyadenylated and initiated 
transcripts are almost exactly equal, and that this is true 
for all the J-Lat clones but none of the other cell lines. It 
is also possible that both the assays for 5′ elongated and 
Pol transcripts gave falsely low results. However, we did 
not see any evidence for inhibition in the ddPCR plots for 
either the 5′ elongated or Pol regions in either the DNA 
or RNA, and we found no evidence for proviral muta-
tions affecting these regions (Additional file  1: Fig. S1A, 
B). Moreover, it seems unlikely that there would be inhibi-
tion in the 5′ elongated and Pol assays but not the PolyA 
assay, since all derive from aliquots of the same reverse 
transcriptase reaction, or that there would be inhibition in 
all of the J-lat clones and none of the other cell lines. A 
third possibility is some form of alternative splicing. Pol 
is removed by the first splicing event and this could con-
tribute to lower levels of Pol, but almost all studies show 
a vast excess of unspliced over spliced HIV RNA, and the 
5′ elongated region is proximal to any known splice donor 
site and should not be reduced by splicing.
The surprising HIV transcription profile in the J-Lats is 
best explained by read-through transcripts that are pol-
yadenylated after the R region of the 5′ LTR, suggesting 
a type of transcriptional interference that also prevents 
elongation. Additional evidence comes from a previously 
published manuscript by Lenasi et al., where the authors 
reported the presence of human/HIV hybrid (read-
through) transcripts in J-Lat 9.2 cells and determined 
where these transcripts terminate by designing a panel of 
RT-PCR assays where the forward primer is in the cellu-
lar integration site and the reverse primers target differ-
ent regions of the proviral genome [29]. They found that 
most of these read-through transcripts were detected by 
a reverse primer in the R region of the LTR (before the 
polyadenylation site) but not by reverse primers beyond 
the 5′ LTR, indicating that most of them terminate some-
where in the distal 5′ LTR [29]. These data corroborate 
the pattern we observed in the J-Lat cells as well as our 
explanation that most of their read-through transcripts 
get polyadenylated in the 5′ LTR. At the same time, 
the strategy used by Lenasi et  al. did not enable them 
to determine whether these read-through transcripts 
become polyadenylated and why transcription stops 
in the 5′ LTR, while our data provide an explanation: in 
these J-Lat clones, the host transcription machinery that 
produces these read-through transcripts often recognizes 
the viral polyadenylation signal that is present in the 5′ 
LTR, leading to termination and polyadenylation.
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The pattern of read-through, prematurely-terminated, 
polyadenylated transcripts observed in the J-Lat clones 
was also observed in the ACH-2 cells and CD4+ T cells 
from one HIV-infected participant, but was very dif-
ferent from the pattern found in U1 cells or most ART-
suppressed individuals. However, in the cell lines studied 
here as well as all ART-suppressed individuals, we also 
found canonical U3-R-U5 “read through” transcripts, 
suggesting that some cellular run-on transcripts may 
continue into the U5 region and possibly beyond the 5′ 
LTR. In the J-Lat 9.2 cells, activation increased all HIV 
transcripts and there was much less difference between 
TAR, LongLTR, Pol, and PolyA, suggesting most of these 
transcripts no longer terminate in the 5′ LTR.
Since transcriptional interference is due to run-on 
transcription from neighboring host genes, the pres-
ence and degree of transcriptional interference are likely 
dependent on the proviral integration site, and transcrip-
tional interference would not be expected in cell lines 
or primary cells where the provirus has integrated into 
non-transcribed regions. The proviral integration site 
and its chromatin environment likely play a role in tran-
scriptional silencing of HIV-1 [15, 36, 37]. Based on their 
studies in J-Lat clone A1 (not studied here), in which the 
provirus is integrated into the X chromosome, Dieu-
donné et al. have proposed that HIV latency is associated 
with the location of the provirus in the nucleus (close to 
the nuclear membrane), and that additional suppression 
of HIV transcription can be caused by spatial proximity 
of the provirus to heterochromatic regions (such as the 
centromere of neighboring chromosome 12) [37]. Con-
sequently, proviral integration in or proximity to non-
transcribed regions, such as centromeres and telomeres, 
could also contribute to transcriptional silencing/latency 
in other cell lines or primary cells.
The ratios of polyadenylated to 5′ elongated HIV tran-
scripts were higher in all latent cell lines compared to 
ART-suppressed individuals, suggesting more polyade-
nylation (less block to “completion”), although in the 
J-Lat cells, many of these “completed” transcripts are 
likely not full length. As measured by the ratio of Tat-
Rev/TAR and Tat-Rev/LongLTR, all latent cell lines had 
higher levels of multiple splicing than in the unstimulated 
cells from ART-suppressed individuals, and these ratios 
were sometimes comparable to activated cells from ART-
suppressed individuals. However, an important caveat 
that could affect these ratios is that the Tat-Rev region is 
frequently deleted in proviruses from ART-treated indi-
viduals [38]. Nonetheless, these data suggest that a block 
to splicing contributes less to latency in these cell lines. 
In terms of the levels of HIV transcriptional initiation, 
block to elongation, and slight block to distal transcrip-
tion/completion, the U1 cell line appeared most similar 
to PBMCs and CD4+ T cells from ART-suppressed indi-
viduals, even though it is a monocytic cell line. Produc-
tively-infected (8E5, activated J-Lat 9.2 and 5A8) cells 
showed little block to HIV transcriptional elongation or 
completion and less block to splicing, suggesting this is 
the pattern of productive infection.
In accord with our bulk analysis, the single-cell levels of 
HIV transcripts varied depending on whether a cell line 
was latently-infected or productively-infected. Within a 
given cell line, marked differences were observed in HIV 
transcript and cellular gene expression at the single cell 
level. The cell-to-cell variability in HIV expression was 
lower for the latent cells (especially U1) and greater for 
the productive cells, particularly for polyadenylated and 
especially multiply-spliced transcripts. In terms of the 
levels (in both bulk and single cell assays) and cellular dis-
tribution of all HIV transcripts except TAR, the ACH-2 
cells appear to be intermediate between the other latent 
cell lines and the productive cell lines. The ACH-2, acti-
vated J-Lat, and 8E5 cells all appeared to show a bimodal 
distribution of Tat-Rev. It is possible that these latter 
three cell types contain a mixture of latently- and pro-
ductively-infected cells or a continuum, either because of 
stochastic, noise-driven differences in HIV transcription 
or variable expression of the cellular genes governing HIV 
transcription and splicing [39, 40]. It is also possible that 
the activation did not exert uniform effects on the J-Lat 
9.2 cells (Fig. 3b). A similar variability in HIV expression 
and/or response to activation may operate in vivo, since 
prior studies using primary cell latency models and cells 
from ART-suppressed individuals have shown that acti-
vation and latency reversing agents induce HIV expres-
sion in only a fraction of infected cells [41–47].
We also observed a surprising degree of heterogene-
ity in expression of some human genes between single 
cells in the same clonal cell line. Some of this heteroge-
neity could reflect variable performance or imprecision 
in the assays, particularly for transcripts present at very 
low copies, although we observed fairly consistent results 
for RNA controls run outside of the C1 platform (HIV 
standards or extracted cellular RNA) and with repeat 
testing of aliquots from single cell cDNA across multiple 
Biomark (PCR) runs. The heterogeneity among clonal 
cells could also reflect stochastic variations in transcrip-
tion or biological differences between single cells, such as 
differences in epigenetics, the phase of the cell cycle, the 
cellular microenvironment, or other factors. Stochastic 
variations in cells of the same type can have major impli-
cations for cell fate decisions [48]. As cell lines are non-
quiescent, cell cycling also could contribute to differences 
in expression of particular transcripts and subsequent 
steady-state levels of protein [49]. Furthermore, RNA 
polymerase II and many other transcription factors can 
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interact with extragenic enhancer sites to produce non-
coding enhancer RNAs (eRNAs) that play a vital role in 
transcriptional regulation [50] and potentially cell-cycle 
progression [49]. Egr1, SP1, and p53 have been recently 
identified to contain eRNA motifs [49], which may con-
tribute to differing levels of RNA expression at the single 
cell level. This single cell variation should be considered 
for future research using these HIV-infected cell lines.
Several lines of evidence suggest that single cell 
expression of the cellular genes we studied, including 
antiviral factors and genes implicated in latency, was 
more highly associated with genetic background than 
with level of HIV expression. First, cell lines derived 
from the same parental strain (ACH-2 and 8E5, unstim-
ulated and activated J-Lat 9.2 cells) clustered together 
despite very different levels of HIV expression. Second, 
the cellular genes seemed to drive most of the differ-
ences in the principal component analysis. Third, there 
was a lack of consistency across cell lines in the human 
transcripts that correlated with HIV transcript lev-
els. Although we only measured cellular gene expres-
sion in one of the 5  J-Lat clones for which we studied 
the bulk cell HIV transcription profile, the fact that all 
5 J-Lat clones showed a very similar HIV transcription 
profile suggests that genetic background (or alterna-
tively the virus, infection conditions, and method to 
select for infected cells) may have a strong influence 
on the mechanisms of latency. Other single cell tran-
scriptomic studies have also shown that cellular genetic 
background drives much of the differential expression 
observed [51, 52]. Sophisticated bioinformatics tools 
are required to distinguish donor-independent, HIV-
modulated changes to gene expression, which will be an 
inherent challenge for all such studies.
Our targeted single-cell approach enabled us to 
study cellular factors of interest, particularly those with 
reported associations with HIV infection and latency 
(Additional file 4: Table S2). We hypothesized that chron-
ically-infected cell lines may exhibit altered expression 
of antiviral-associated genes, such as essential sensors 
of viral RNA (RIG-I and MDA5), to support the persis-
tence of HIV. Although we did not observe a significant 
negative correlation between RIG-I and HIV transcripts, 
it is possible that lower abundance of RIG-I might con-
tribute to impaired RNA-sensing capability in the set-
ting of ongoing viral transcription (as occurs in 8E5 and 
ACH-2), permitting HIV persistence in the absence of 
robust PRR signaling. In addition to lower basal RIG-I 
expression, HIV protease reportedly sequesters RIG-I to 
evade the RIG-I signaling cascade [53], which could also 
contribute to impaired innate immune responses to HIV 
transcription. Interestingly, J-Lat 9.2 cells did not express 
IFNα, further suggesting that despite upregulation of 
RIG-I, the cellular response to infection could be drasti-
cally attenuated.
Reverse-transcribed HIV DNA can trigger C-GAS-
mediated activation of STING, an adaptor protein that 
subsequently induces Type I interferons and cytokines 
[54]. Although we did not detect IFNα in J-Lat 9.2 irre-
spective of activation, the increase in STAT1 that cor-
related with polyadenylated HIV transcript expression 
(PolyA: P < 0.004; Additional file 12: Fig. S9) suggests that 
activation of the JAK/STAT pathway may be driven by 
other IFNs such as IFNγ (IFI16 is upregulated upon J-Lat 
9.2 activation; Fig.  4a) [55] or other cytokines [56]. The 
low and variable expression of cellular antiviral defenses 
may have contributed to or selected for survival of these 
cell lines after infection, especially for the ACH-2 and 
8E5 cells that express more HIV. It is possible that a 
similar phenomenon contributes to the survival of some 
HIV-infected cells in vivo, especially those that go on to 
form the latent reservoir. Several reports have described 
impairment in IFN-mediated antiviral responses in HIV-
infected individuals, and PBMCs from HIV-positive 
individuals show impaired IFN-stimulated responses to 
transfected HIV [57–60].
In J-Lat 9.2 cells, we found that expression of many cel-
lular genes, including housekeeping genes, correlated 
with multiple HIV targets, suggesting a general associa-
tion between overall levels of cell transcription and viral 
transcription, which makes sense given the mechanism 
of transcriptional interference in this cell line. However, 
a subset of the genes showed higher r values and may be 
more closely associated with HIV transcription, including 
CCR5, BCL11B, CDK9, CREBBP, and STAT1 (P < 0.00012 
for all; Fig.  5, Additional file  12: Fig. S9). Some of these 
correlations are expected. CDK9 together with cyclin 
T1 comprise P-TEFb, which associates with HIV TAR 
[61] and is a target for HIV Tat-mediated transactivation 
[62]. Similarly, it is understood that CREBBP is recruited 
by HIV Tat to the  5′-LTR to enhance transcription [63]. 
However, somewhat paradoxically, the expression of 
BCL11B, which represses transcription from the LTR to 
mediate HIV-silencing [64], was also associated with TAR 
and Gag expression in J-Lat 9.2 cells (P < 4.6 × 10−5; Fig. 5, 
Additional file 12: Fig. S9). Interestingly, we also observed 
a correlation between STAT1 RNA expression and TAR 
and PolyA in J-Lat 9.2 (P < 0.004; untreated and activated, 
respectively), suggesting the induction of the Type 1 IFN 
JAK/STAT pathway in these chronically-infected cells, 
in line with data from other J-Lat clones implicating the 
JAK/STAT pathway in latent virus reactivation [65].
Despite the correlations in J-Lat 9.2 cells, we did not 
observe a consistent relationship between expression of 
any cellular gene in our panel and HIV transcripts across 
all cell lines. For instance, CD69 correlated positively 
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with HIV expression in J-Lat 9.2 and activated J-Lat 9.2, 
but not in productively-infected 8E5, or in ACH-2, where 
there was a trend toward a negative correlation (Fig. 5a). 
Our finding that no cellular gene consistently correlated 
with HIV expression was not unexpected, given that 
these cell lines exhibit fundamental differences in their 
mechanisms of latency and cellular gene expression.
Chronic infection alters expression of many cellular 
genes relative to the parental cell line, such as genes 
encoding transcription factors, proteasome compo-
nents, factors that control immune function, and apop-
tosis in ACH-2 relative to its parental cell line, A3.01 
[66]. The upregulation of anti-apoptotic genes includ-
ing chaperonins, heat shock proteins, histone deacety-
lases and proteasome subunits has been implicated 
in contributing to the maintenance of HIV latency in 
ACH-2 [67]. Activation of the J-Lat 9.2 cells also led to 
upregulation of many genes, including those involved in 
pathogen sensing, immune responses, and anti-apop-
totic functions, suggesting that activation and/or viral 
expression triggers a number of signaling cascades. 
Within the ACH-cells, 8E5 cells, and activated J-Lats, 
expression of multiply-spliced Tat-Rev was associated 
with differential expression of cellular genes involved in 
apoptosis and survival. Cellular and immune defenses 
can trigger apoptosis in response to viral products, 
while anti-apoptotic pathways may contribute to the 
survival of immortalized cell lines, especially in the face 
of productive HIV infection. Emerging evidence sug-
gests that anti-apoptotic pathways may also contribute 
to the survival of HIV-infected cells and persistence of 
proviral clones in vivo [68–70], and these pathways may 
be targets for new therapies aimed at killing infected 
cells and curing HIV [71].
The limitations of this study should be acknowledged. 
Subculturing of cell lines has been reported to result in 
perturbed morphology, growth rates, protein expression 
and response to stimuli [72–74]. Despite the low passage 
of cells used in this study [2–5], it is possible that aber-
rant changes occur on a shorter scale in cell lines, and 
ongoing replication and integration into unique sites [28] 
could contribute to the variability in gene expression that 
we observe at the single cell level. These data underscore 
the need for minimizing subculturing of cell lines prior to 
undertaking experiments.
As measured by HIV DNA levels per million cells, we 
observed less than one HIV provirus per cell in some of 
the cell lines (including 8E5 and J-Lat 6.3, 8.4, and 15.4). 
It is possible that some cells have lost the HIV provirus 
or harbor mutated proviruses, consistent with previ-
ous reports [28, 31, 32]. HIV DNA levels were consist-
ent across 5 different regions (aside from the expected 
twofold excess of targets confined to the LTR, which is 
present at each end of the provirus), arguing against 
selective mutation or assay insensitivity in one proviral 
region. Moreover, frequencies of < 1 provirus/cell were 
observed with two widely-accepted methods of normal-
izing to cell numbers. However, the cell equivalents as 
determined by DNA mass and TERT tended to exceed 
the pre-extraction cell counts (DNA mass was closer), 
which suggests error in the NanoDrop or TERT meas-
urements. It is possible that some cell lines have a dupli-
cation of the TERT gene and/or some chromosomes, 
especially if the cells are polyploid or a substantial pro-
portion of cells are progressing through the cell cycle. 
Duplication of the TERT gene and/or chromosomes that 
do not contain the provirus could lead to underestima-
tion of the HIV DNA (infection frequency) as normalized 
to TERT or DNA mass. In support of the latter explana-
tion, the infection frequency of the 8E5 cells was higher 
when measured in single cells (43/44) than bulk cells. 
However, the sensitivity to detect an infected cell may be 
higher in the single cell assays due to the inclusion of 7 
different HIV targets, the ability to detect RNA as well as 
DNA, and the inclusion of a pre-amplification step prior 
to PCR.
A limitation inherent to all transcriptomic-based stud-
ies is the reality that protein expression is influenced by 
many post-transcriptional processes, including RNA pro-
cessing (alternative/differential splicing); RNA stability; 
translational regulation (presence of regulatory elements 
in the 5′ untranslated region or tRNA availability [75]); 
and differential stability, regulation, and post-transla-
tional modification of protein species [49]. RNA expres-
sion does not infer levels of protein generated, nor does 
it provide insight into the phosphorylation states of their 
residues [49] or functionality, which can limit our inter-
pretation of some observations. For instance, although 
we observed a correlation between STAT1 RNA expres-
sion and HIV transcripts in J-Lat 9.2, HIV proteins can 
inhibit the phosphorylation of STAT1 protein [76] or 
target STAT1 for proteosomal degradation [77] to per-
turb antiviral responses via the JAK/STAT pathway. As 
another example, 8E5 cells have been shown to transcribe 
CD4 RNA at levels similar to their parental CD4+ cell 
line, but show low surface expression of CD4 because 
the protein is sequestered with HIV Env in the rough 
endoplasmic reticulum [78]. Similarly, although J-Lat 
9.2 exhibited relatively high CD3 RNA levels (Fig.  4a) 
in both non-activated and activated states, it is possible 
that the subsequent protein expressed may be limited or 
less functional. J-Lat clones 6.3, 8.4 and 11.1 are unre-
sponsive to activation using αCD3/αCD28 despite strong 
responses to phytohemagglutinin, which also stimulates 
signaling cascades involving TCR/LCK/p38 activation 
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[20]. This finding in closely related J-Lat clones could 
point to suboptimal function of CD3 within these clones.
RNA and protein levels can also be influenced by other 
factors mentioned above, including intrinsic ‘transcrip-
tional noise,’ epigenetics, cell cycle, and the microenvi-
ronments of cells [79], which were not assessed in this 
study. Despite these limitations, our data provide valu-
able insights into the relationship between the HIV tran-
scription profile and transcriptome of widely-used cell 
lines.
Conclusions
Although primary cell models are increasingly employed 
in studies of HIV latency, continued research efforts uti-
lize HIV-infected cell lines to evaluate new assays for HIV 
persistence, investigate the molecular mechanisms that 
underlie the establishment/maintenance of HIV latency, 
and test new therapies designed to disrupt latency [80–
87]. In order to best employ these cell lines, it is critical 
to understand how they differ from each other and from 
cells from ART-treated individuals in the mechanisms 
underlying latent HIV infection. We used novel HIV 
transcription profiling and leading-edge single cell tech-
nology to compare widely-used cell line models of latent 
and productive HIV infection. We found marked differ-
ences between each cell line and cells from ART-treated 
individuals in the HIV transcriptional blocks underly-
ing latency, and between cell lines in single cell expres-
sion of viral and cellular genes. Furthermore, despite the 
clonality of the cells, viral genetics, and integration sites, 
single cell-data revealed significant variability in viral 
and cellular expression profiles. Use of these cell lines 
for HIV research to address a particular research ques-
tion should take into account the differences in viral and 
cellular gene expression patterns observed here. Despite 
the differences between HIV-infected cell lines, some 
findings were shared across cell lines, such as reduced 
expression of cellular antiviral factors and a relationship 
between expression of multiply-spliced HIV RNA and 
expression of human genes involved in apoptosis or sur-
vival. These factors may contribute to the maintenance 
and persistence of the latent reservoir in vivo. To further 
investigate the mechanisms of latency and develop new 
therapies that more specifically and more efficiently dis-
rupt latent HIV infection, novel single cell methodologies 
such as those described in this study should be applied to 
primary cell latency models and unstimulated cells from 
ART-treated individuals.
Methods
Study participants
The study participants were HIV-infected adults on 
suppressive ART from two cohorts (median age = 51; 
median CD4 count = 611 cells/mm3; median years of 
suppression = 5). Cryopreserved PBMCs  (107 cells) were 
available from 9 study participants in the Reservoirs and 
Drug Levels (RADL) study [10]. CD4+ T cell pellets, 
which had been isolated using negative selection from 
the blood and either frozen immediately or after activa-
tion for 2 days with anti-CD3/CD28 and antiretrovirals, 
were available from 7 ART-suppressed study participants 
recruited prospectively and sequentially from the San 
Francisco VA Medical Center.
Cell culture and activation
Cell lines were obtained through the NIH AIDS Research 
Reagent Program (NIH ARRRP), Division of AIDS, 
NIAID, NIH: ACH-2, 8E5 and U1 (U937) from Dr. 
Thomas Folks, and J-Lat Full Length Clones (6.3, 8.4, 9.2 
and 15.4) from Dr. Eric Verdin. J-Lat Full Length clone 
5A8 was obtained through Dr. Warner Greene. J-Lat full 
length 5A8, 6.3, 8.4, 9.2 and 15.4 cells were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium 
(Invitrogen Life Technologies, Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich, St. Louis, MO), 100 U/ml penicillin, 100  mg/
ml streptomycin and 2  mM  l-glutamine (Invitrogen, 
Carlsbad, CA). ACH-2 cells were cultured in RPMI 
1640 supplemented with 10% FBS, 10  mM HEPES, and 
2  mM  l-glutamine. HIV-1 infected U937 cells (U1) 
were cultured in RPMI 1640 containing 10% FBS and 
2  mM  l-glutamine. HIV-1 LAV infected 8E5 cells were 
cultured in RPMI 1640 supplemented with 10% FBS. 
Cells were incubated at 37  °C, 5%  CO2, and passaged 
twice a week following NIH ARRRP recommendations. 
J-Lat 5A8 and 9.2 cells were activated in bulk by culture 
for 24  h with 10  ng/ml phorbol 12-myristate 13-acetate 
(PMA) and 1uM Ionomycin (Sigma). Cells were cultured 
in parallel with unstimulated J-Lat (clone 9.2 and 5A8) 
cells of the same passage. Following stimulation, J-Lat 9.2 
and 5A8 cells (unstimulated and stimulated) were pre-
pared for bulk HIV RNA and DNA analysis, and J-Lat 9.2 
cells (unstimulated and stimulated) loaded into the either 
5–10 µm C1 integrated fluidic circuit (IFC) [unstimulated 
cells] or 10–17 µm C1 IFC [stimulated cells] as described.
Bulk HIV RNA and DNA quantification
For all the cell lines, at the lowest passage number as 
possible (< 5 in all cases), when the viability was above 
90% and after 24  h of activation using PMA/Ionomy-
cin, aliquots of 2 × 106 cells were immediately frozen as 
cell pellets. Total cellular RNA and DNA were isolated 
using Trireagent following manufacturer’s instructions. 
RNA and DNA concentrations were quantified using UV 
spectrophotometry (NanoDrop 1000). TAR levels were 
quantified by 3-step polyadenylation-RT-ddPCR [9, 88], 
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while Read-through, LongLTR, Pol, Nef, PolyA and Tat-
Rev transcripts were quantified by 2-step-RT-ddPCR, 
as previously described [9, 10], except for ACH-2, for 
which the TAR sequence was amplified using a different 
probe (5′ AGC CTG GGA GTT C 3′) to avoid sequence 
mismatch caused by the mutation at nucleotide +  37 
(C⟶T) in the TAR loop of ACH-2 cells [18]. Cellular 
DNA was fragmented using QIAshredder columns and 
used to quantify total HIV DNA for TAR, Read-through, 
LongLTR, Pol and Nef, using the same primer–probe 
sets used for HIV RNA transcripts, and the human gene 
TERT. All samples were tested in duplicate. “No RT” 
reactions and PBMCs from HIV negative donors were 
tested in parallel to check DNA contamination or as 
negative controls, respectively. HIV RNA transcripts and 
HIV DNA were normalized to million cells using DNA 
mass (by NanoDrop, assuming 1 μg DNA equals 160,000 
cells) and the TERT gene copies in the total extracted 
DNA, the resuspension volumes of the DNA or RNA, 
and the proportions going into the RT and/or ddPCR 
reactions. The average levels of each HIV transcript per 
provirus were calculated by dividing levels of each HIV 
RNA by levels of the LongLTR DNA (present in one 
copy per provirus), and by dividing each HIV RNA by 
levels of the same HIV DNA region (corrected for 2 LTR 
regions per provirus).
Primer selection
Assay targets were selected based on their reported asso-
ciation with T cell function, HIV infection, and HIV 
latency, and included genes for housekeeping transcripts, 
T cell function and phenotype, HIV coreceptors, markers 
of activation/proliferation/senescence, cytokines, genes 
involved in apoptosis or pyroptosis, antiviral or restric-
tion factors, and genes implicated in HIV latency, tran-
scription, mRNA end processing, and splicing. Genes 
were selected from the catalogue of inventoried and 
custom TaqMan™ primers and probes for qPCR (Inv-
itrogen Life Technologies). In instances where multiple 
TaqMan™ primer/probes sets were available for the same 
target, the following selection criteria were applied: (1) 
primers spanned exon boundaries to selectively amplify 
mRNA, (2) size of amplicon (120  bp or less), and (3) 
highest number of reference sequences available. In some 
cases, not all of these criteria could be met, in which case 
the ‘preferred’ option, as recommended by Life Technol-
ogies was selected.
Custom HIV primers
Custom TaqMan™ primer/probe sets were designed 
based on transcription profiling assays [9, 89]. Primer and 
probe sequences were the same as those described previ-
ously for ddPCR and RT-ddPCR [9, 90]. The performance 
of these assays in the single cell C1 platform was assessed 
using two standards: (1) an unspliced genomic HIV RNA 
(virion) standard, which detects all assays except for 
multiply-spliced Tat-Rev; and (2) an in vitro transcribed, 
synthetic, read-through, multiply-spliced, polyadenylated 
HIV RNA standard, which detects all assays except Gag 
and Pol.
All primer/probe sets were assessed based on efficient 
amplification (where the signal doubles with each PCR 
cycle), linearity (where the final signal is proportional to 
input RNA) and performance using bulk donor PBMCs 
and RNA (~ 200 cells). Negative and No-RT controls 
were routinely included in each experiment. Negative 
controls were consistently negative for amplification.
Single cell partitioning, RT, and preamplification using 
the C1 assay system
Cells were counted using an automated counter (TC-
20, Bio-Rad, Hercules, CA) and manual counting using 
a hemocytometer. Cells were washed twice in PBS and 
resuspended at a concentration of 1200 cells/µL. Cells (6 
µL) and reagents (Ambion Single cell-to-CT qRT-PCR 
kit, Thermo Fisher, Waltham CA) were loaded into the 
C1 integrated fluidic circuits (IFCs) as per manufacturer’s 
recommendations.
Validations were performed to determine optimal 
cell concentration, cell buoyancy, and input for highest 
single-cell capture rate. Cell capture was evaluated by 
microscopy directly following ‘Cell Load’ script. Single, 
healthy-appearing cells were selected for downstream 
analysis post-C1 protocol. Cell lysis, reverse transcription 
and cDNA pre-amplification were carried out using the 
C1 instrument (Fluidigm Corp., San Francisco, CA).
The IFC size selected was based on expected cell size: 
5-10  µm chips were used for unstimulated J-Lat (clone 
9.2), 8E5, U1 and ACH-2, whereas 10-17  µm IFC were 
selected for stimulated J-Lat cells. Following C1 assay 
completion, cDNA was harvested and diluted 1 in 8 in 
C1 DNA Dilution buffer (Fluidigm Corp.) and stored at 
− 20 °C prior to use.
Gene expression analysis using Biomark HD system
TaqMan™ primers/probes (Thermo Fisher) and sample 
cDNA were dispensed into discrete inlets of a 96 ×  96 
Dynamic Array microfluidic chip (Fluidigm Corp.) as per 
manufacturer recommendations.
Forty cycles of PCR were performed using the Biomark 
instrument (Fluidigm Corp). Data were analyzed using 
the Fluidigm Real-time PCR Analysis software suite (ver-
sion 4.1.3, Fluidigm Corp.) and the SINGuLAR Analy-
sis Toolset Software (version 3.6.2, Fluidigm Corp.) in R 
(version 3.0.2, open source) to validate assay performance 
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and in instances where ‘failed’ reactions were reported, 
manual verification was performed. Where fluorescence 
data displayed characteristics of logarithmic ampli-
fication, and the expected “Ct” (threshold cycle) was 
achieved, reactions were designated “passed”.
Statistical analysis
Single cell analyses were performed using R. Principal 
component analysis was performed using the Facto-
MineR v1.41 package [91], and t-SNE analysis was per-
formed using the Rtsne v0.15 package [92]. Differential 
gene expression analysis was performed using Poisson 
generalized linear model as implemented in Seurat v2.3.4 
[93, 94]. All correlation analyses were performed using 
Spearman correlations. P-values were adjusted for false 
discovery rate (FDR) [95]. Hierarchical clustering analy-
ses were performed using Ward’s method [96] as imple-
mented in pheatmap v1.0.12. All plots were generated 
using the ggplot2 v3.1 and pheatmap v1.0.
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Additional file 1: Fig. S1. Bulk cell HIV DNA and RNA levels. A Total HIV 
DNA copies per million cells (normalized by DNA mass). B Total HIV DNA 
copies per million cells (normalized by TERT). C HIV RNA levels normal‑
ized to million cells (by DNA mass). D Cell‑associated HIV RNA copies per 
provirus, as normalized by ratio of each HIV RNA to the corresponding HIV 
DNA region. For PBMCs, CD4+ T cells, and activated CD4+ T cells from 
HIV‑infected ART‑suppressed individuals (B, C), each individual is shown 
as a dot, the column height indicates the median, and bars represent 
25–75%. 
Additional file 2: Fig. S2. Progression through HIV transcription stages. 
This schematic shows relative levels of HIV transcription initiation, elonga‑
tion, completion and multiple splicing quantified in the myeloid cell line 
U1; the lymphoid cell lines ACH2, 8E5, J‑Lat clones and activated J‑Lat 
clones; and in PBMCs, CD4+ T cell and activated CD4+ T cells from HIV‑
infected ART‑suppressed individuals. The scale depicts the maximal block 
to transcription (red) to no transcriptional block (green). For each cell line, 
the blue arrow indicates the comparative progression through/block to 
transcription at each stage. 
Additional file 3: Table S1. caHIV RNA transcript ratios. 
Additional file 4: Table S2. Complete assay panel. 
Additional file 5: Fig. S3. Sensitivity for HIV RNA in the single‑cell Biomark 
HD platform. Each row represents a single sample. For donor PBMCs, the 
equivalent of 10 cells (RNA) was added to each reaction as a negative 
control. Two standards were used to assess the sensitivity of each HIV 
assay: a synthetic multiply‑spliced HIV RNA standard (which contains TAR, 
LongLTR, Nef, PolyA, and Tat‑Rev but not Gag or Pol) and an HIV virion RNA 
standard (which contains TAR, LongLTR, Gag, Pol, Nef, and PolyA, but much 
lower levels of Tat‑Rev). Both standards were added to each independent 
Biomark assay at 5, 10, 50 and 500 copies. All assays except PolyA could be 
detected down to 5 copies, but PolyA was less efficient than the other HIV 
assays in this platform. 
Additional file 6: Fig. S4. Reproducibility of independent Biomark HD 
experiments. A Aliquots of cDNA from individual cells were tested in 
separate Biomark HD experiments. Y and X axes show the expression lev‑
els (40‑CT) of each HIV target (left plot) and cellular gene (right plot) from 
separate Biomark HD runs. R values are from Spearman correlations. B 
Dropout occurrence for HIV and gene expression assays. The table shows 
all cases for which an HIV or cellular target was detected in one Biomark 
HD experiment but not another, along with the particular cell line and 
expression levels. 
Additional file 7: Table S3. Number of single‑cells analyzed across cell 
lines. 
Additional file 8: Fig. S5. T‑distributed stochastic neighbor embedding 
(tSNE) plot. tSNE plot of gene expression profiles representing the cluster‑
ing of individual cells post‑ComBat adjustment. ComBat adjustment was 
performed to control for batch effects. Single‑cells for each cell line are 
indicated by color and symbols denote independent assays (batch). 
Additional file 9: Fig. S6. Principal component analysis. Correlation coef‑
ficients of top principal components and 95 genes. Each row represents a 
different dimension in the PCA analysis; each column indicates a different 
cellular gene or HIV target. No expression of TIGIT was detected and 
was subsequently excluded from further analysis. The color scale (right) 
denotes Pearson coefficients. Dendrograms (above) show unsupervised 
clustering. 
Additional file 10: Fig. S7. Single cell variation in cellular and HIV expres‑
sion. Cells are grouped on basis of cell line. Each vertical line represents a 
single cell. All cellular (89) and HIV (7) targets are shown on separate rows. 
The blue to red scale (right) denotes expression levels (40‑CT). Dendro‑
grams (left) show unsupervised clustering. Each cell line and category of 
gene target (antiviral/restriction factor, HIV transcription/latency, T cell 
phenotype/function, housekeeping, HIV target) is indicated by a different 
color. 
Additional file 11: Fig. S8. False correlations driven by non‑detection 
of cellular and HIV targets. Shown are correlations between Tat‑Rev and 
expression of C‑GAS (left panel) and HLA‑DR (right panel) in U1 cells. 
Additional file 12: Fig. S9. Positive correlations between expression of 
cellular and HIV targets in J‑Lat 9.2 (untreated and activated). Positive cor‑
relations between cellular and HIV targets in A non‑activated J‑Lat 9.2 and 
B activated J‑Lat 9.2. R and p values are from Spearman correlations. 
Additional file 13: Fig. S10. Differentially expressed genes in unstimu‑
lated vs. activated J‑Lat 9.2 cells. Each dot represents a separate gene 
or HIV target. The X axis represents the  log2 fold change and the y‑axis 
denotes the − log10(P value).
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